Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia.

Autor: Scher N; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France. n.scher@rt-hartmann.fr.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France. n.scher@rt-hartmann.fr., Boudabous H; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France., Partouche J; Paris School of Business, Living Health Chair, Paris, France.; Léonard de Vinci Pôle Universitaire, Research Center, Paris, France., Rezaee-Vessal S; Paris School of Business, Living Health Chair, Paris, France.; Léonard de Vinci Pôle Universitaire, Research Center, Paris, France., Ihout P; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France., Rizzo C; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France., Lamallem H; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France., Bauduceau O; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France., Darmon I; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France., Bollet M; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France., Draghi C; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France., Toledano A; Rafael Institute, Integrative Medicine Center, Levallois-Perret, France.; Hartmann Oncology Radiotherapy Group, Hartmann Radiotherapy Institute, Levallois-Perret, France.; Department of Integrative Medicine, Conservatoire National des Arts et Metiers, Paris, France.
Jazyk: angličtina
Zdroj: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2024 Oct 22; Vol. 32 (11), pp. 743. Date of Electronic Publication: 2024 Oct 22.
DOI: 10.1007/s00520-024-08929-x
Abstrakt: Purpose: Chemotherapy-induced neutropenia poses a significant risk to cancer patients, with pegfilgrastim being commonly used for its prevention. While pegfilgrastim can be administered via prefilled syringe or pen device, patient preferences and experiences with these delivery methods remain unclear.
Methods: We conducted a prospective, open-label, randomized, observational trial (NCT05910164) at the Rafael Institute, France, comparing patient preferences for pegfilgrastim administration using a prefilled syringe versus a prefilled pen device. Patients undergoing chemotherapy and requiring pegfilgrastim were enrolled and randomized 1:1 to receive either syringe or pen first, with crossover administration. Questionnaires assessed patient preferences, learning experiences, autonomy, pain levels, emotional responses, satisfaction with nursing care, and empowerment.
Results: Among 150 randomized patients (mean age 58 years; 69% female), both groups showed a preference for the pen device, with significantly higher mean scores favoring pen administration (4.94 ± 1.70 vs. 4.27 ± 1.84; p = 0.00106). Patients reported significantly lower perceived pain with pen administration and stronger positive emotions compared to syringe use. Satisfaction with nursing care was higher with syringe use. Empowerment levels were similar across groups but significantly stronger when using the pen in complete autonomy.
Conclusion: A preference for pegfilgrastim administration via the pen device was observed, though this may have been influenced by the administration sequence and the absence of syringe self-administration. The insights gained can help inform clinical decision-making and improve patient-centered care in managing chemotherapy-induced neutropenia.
Trial Registration: NCT05910164 on June 15, 2023.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: